

Plasminogen activators - Pipeline Insight, 2022

<https://marketpublishers.com/r/P9D3D8AEA69EN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: P9D3D8AEA69EN

Abstracts

This report can be delivered to the clients within 48 hours

DelveInsight's, "Plasminogen activators - Pipeline Insight, 2022" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Plasminogen activators pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Plasminogen activators Understanding

Plasminogen activators: Overview

Plasmin is the serine protease responsible for degradation of fibrin. Two forms of the zymogen precursor plasminogen circulate in plasma, the native more abundant form, Glu-plasminogen, and the intermediate form Lys-plasminogen, formed by cleavage of the N-terminal peptide from Glu-plasminogen. The plasminogen activator (PA) system is an extracellular proteolytic enzyme system associated with various physiological and pathophysiological processes. The first-generation plasminogen activators like streptokinase and urokinase are compounds found in nature that lack fibrin selectivity, while second-generation activators including t-PA and scu-PA are natural human proteins that possess some fibrin selectivity and can be produced either by selected human cell cultures or by recombinant DNA methods. The third-generation plasminogen

activators are numerous compounds that are in clinical development and possess enhanced properties as a result either of chemical modification or of the application of recombinant DNA technology.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Plasminogen activators R&D. The therapies under development are focused on novel approaches for Plasminogen activators.

Plasminogen activators Emerging Drugs Chapters

This segment of the Plasminogen activators report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Plasminogen activators Emerging Drugs

TMS-007: TMS

TMS-007 is a plasminogen activator based small molecule that is associated with breaking down blood clots, and is believed to inhibit local inflammation at the site of thrombosis. TMS-007 is designed to restore blood flow following acute stroke. TMS-007 is currently being evaluated in a Phase 2 study in Japan, in patients with acute ischemic stroke (AIS).

Recombinant staphylokinase: Supergene

Recombinant staphylokinase is a Plasminogen activators containing Alteplase as the active substance. It is single chain molecule that consists of 138 amino acids. When staphylokinase is added to human plasma containing a fibrin clot, it preferentially reacts with plasmin at the clot surface, forming a plasmin-staphylokinase complex. The drug is in Phase III clinical evaluation for the treatment of pulmonary embolism and stroke.

Further product details are provided in the report.....

Plasminogen activators: Therapeutic Assessment

This segment of the report provides insights about the different Plasminogen activators drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Plasminogen activators

There are approx. 10+ key companies which are developing the Plasminogen activators. The companies which have their Plasminogen activators drug candidates in the most advanced stage, i.e. Phase III include, Supergene.

Phases

DelveInsight's report covers around 10+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Plasminogen activators pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Plasminogen activators: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Plasminogen activators therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Plasminogen activators drugs.

Plasminogen activators Report Insights

- Plasminogen activators Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Plasminogen activators Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing Plasminogen activators drugs?

How many Plasminogen activators drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Plasminogen activators?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Plasminogen activators therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Plasminogen activators and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Genentech

TMS

Tasly Pharmaceutical

Cereno Scientific

Supergene

Boehringer Ingelheim

Chiesi Farmaceutici

Key Products

Tenecteplase

TMS 007

Prourokinase recombinant

CS-1

Recombinant staphylokinase

Alteplase

CUSA-081

Contents

Introduction

Executive Summary

Plasminogen activators: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Plasminogen activators – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Plasminogen activators companies' collaborations, Licensing, Acquisition -Deal Value

Trends

Plasminogen activators Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Recombinant staphylokinase: Supergene

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

TMS 007: TMS

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

CS-1: Cereno Scientific

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Plasminogen activators Key Companies

Plasminogen activators Key Products

Plasminogen activators- Unmet Needs

Plasminogen activators- Market Drivers and Barriers

Plasminogen activators- Future Perspectives and Conclusion

Plasminogen activators Analyst Views

Plasminogen activators Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Plasminogen activators

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Plasminogen activators
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Plasminogen activators - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/P9D3D8AEA69EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P9D3D8AEA69EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970